CCO Oncology Podcast

In this episode, Jeff P. Sharman, MD; Matthew S. Davids, MD, MMSc; and Anthony Mato, MD, MSCE, answer questions from a live CCO webinar on current best practices and emerging strategies in BTK inhibitor therapy for patients with chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL), with questions including:

• For patients with CLL, when should acalabrutinib-, ibrutinib-, or venetoclax-based regimens be considered?
• What is the optimal therapy for a patient with del(17p) CLL?
• When should an anti-CD20 antibody be added to BTK inhibitor therapy for patients with CLL?
• What are best practices in the use of BTK inhibitors for patients with MCL?
• How can BTK inhibitor resistance occur?
• How might investigational noncovalent BTK inhibitors be used should they be approved?
• What are key adverse events with BTK inhibitors?

Presenters:

Jeff P. Sharman, MD (chair)
Medical Director
Hematology Research
US Oncology
Willamette Valley Cancer Institute
Eugene, Oregon

Matthew S. Davids, MD, MMSc
Associate Professor of Medicine
Harvard Medical School
Director of Clinical Research
Division of Lymphoma
Dana-Farber Cancer Institute
Boston, Massachusetts

Anthony Mato, MD, MSCE
Associate Professor
Division of Leukemia
Memorial Sloan Kettering Cancer Center
New York, New York

Content based on an online CME program supported by an educational grant from Lilly. For further information concerning Lilly grant funding, visit https://bit.ly/3wXOsV5.

Link to full program:
https://bit.ly/3NEpsYQ

In this episode, Jyoti D. Patel, MD, and Diwakar Davar, MD, discuss several studies investigating agents targeting TIGIT, an emerging immune checkpoint target with promising early-phase clinical trial results. The episode includes a comprehensive explanation of TIGIT, how the TIGIT pathway functions, and the potential role of TIGIT inhibition for the treatment of cancer, including analyses from ongoing clinical trials such as CITYSCAPE, PACIFIC-8, ARC-7, and SKYSCRAPER-01.

Presenters:

Jyoti D. Patel, MD
Professor of Medicine
Division of Hematology and Oncology
Medical Director for Thoracic Oncology
Assistant Director for Clinical Research
Associate Vice Chair of Clinical Research
Department of Medicine
Robert H. Lurie Comprehensive Cancer Center
Northwestern University
Chicago, Illinois

Diwakar Davar, MD
Assistant Professor, Melanoma and Phase I Therapeutics
Division of Hematology/Oncology
Department of Medicine
University of Pittsburgh Hillman Cancer Center
Pittsburgh, Pennsylvania

Link to the complete program, including an online text module with downloadable slidesets, ClinicalThought commentaries, and an additional podcast on this topic:
https://bit.ly/3r9BLmB

In this episode, Prof Isabelle Ray Coquard, MD, PhD, and Ignace Vergote, MD, PhD, share their thoughts on key studies of interested presented at the 2022 ESGO annual meeting in Berlin, Germany, including:

• Phase III CALLA trial of durvalumab combined with and following chemoradiotherapy in locally advanced cervical cancer

• Geneva HRD test: validation of samples from PAOLA-1 dataset using Geneva laboratory–developed test

• Validation of NOGGO-GIS HRD assay using samples from the PAOLA-1 trial

• Survival results from phase III ARIEL3: maintenance rucaparib vs placebo following response to platinum-based chemotherapy for recurrent ovarian cancer

Presenters:

Isabelle Ray-Coquard, MD, PhD
Professor of Department of Medical Oncology
Clinical Science Institute of the Léon Bérard Center
Lyon, France

Ignace Vergote, MD, PhD
Professor Em. of Department of Obstetrics and Gynecologic Oncology
University Hospitals Leuven
Leuven, Belgium

Content supported by educational grants from AstraZeneca, GlaxoSmithKline, Karyopharm Therapeutics, and Merck Sharp & Dohme Corp.

Link to full program, including a downloadable highlights slideset, and ClinicalThought commentaries:
https://bit.ly/3SSSqpN

In this episode, Kathleen Moore, MD, MS, and Nicoletta Colombo, MD, PhD, provide expert insights on key updates and new clinical trial data presented at the 2023 ASCO Annual Meeting for cervical, endometrial, and ovarian cancers, including:

• ENGOT-EN6-NSGO/GOG-3031/RUBY: phase III study of dostarlimab plus chemotherapy followed by dostarlimab maintenance in primary advanced or recurrent endometrial cancer outcomes by BICR
• CCTG CX.5-SHAPE: phase III trial of radical hysterectomy and pelvic node dissection compared with simple hysterectomy and pelvic node dissection in low-risk, early-stage cervical cancer
• Final OS results from KEYNOTE-826: phase III study of CT with or without pembrolizumab as first-line treatment for patients with persistent, recurrent, or metastatic cervical cancer
• DUO-O: a randomized, placebo-controlled phase III study of durvalumab plus carboplatin, paclitaxel, and bevacizumab and then maintenance bevacizumab, durvalumab, and olaparib in patients with newly diagnosed advanced ovarian cancer and no BRCA1/2 gene alteration
• MIRASOL: an initial report from a phase III study of mirvetuximab soravtansine vs investigator’s choice of CT in platinum-resistant ovarian cancer with high expression of FRα
• Patient-reported outcomes from the phase III ENGOT-EN6/RUBY trial of dostarlimab plus standard-of-care CT in primary advanced or recurrent endometrial cancer

Presenters:
Kathleen Moore, MD, MS
Associate Director, Clinical Research
Department of Gynecologic Oncology
Stephenson Cancer Center, University of Oklahoma
Oklahoma City, Oklahoma

Nicoletta Colombo, MD, PhD
Associate Professor of Obstetrics and Gynecology
European Institute of Oncology
University of Milan-Bicocca
Milan, Italy

Content supported by educational grants from AstraZeneca, GlaxoSmithKline, Merck Sharp & Dohme Corp., Novocure Inc., and Seagen Inc.

Link to full program, including a downloadable highlights slideset and ClinicalThought commentaries:

bit.ly/43Q5CBI

In this podcast episode,Sandra E. Kurtin, PhD, ANP-C, AOCN, discusses nursing perspectives on avoiding adverse reactions to BTK inhibitor therapy. Topics in this first of 2 podcasts on avoiding AEs include:

• Pharmacokinetics
• Drug metabolism
• Drug–drug interactions
• Drug–food interactions
• The role of CYP enzymes
• Foods to avoid
• Medication review

Presenter:

Sandra E. Kurtin, PhD, ANP-C, AOCN
Director, Advanced Practice and Clinical Integration
The University of Arizona Cancer Center
Assistant Professor, Clinical Medicine
Adjunct Clinical Professor, Nursing
The University of Arizona
Tucson, Arizona

CE/AAPA credit available by visiting the online program:
https://bit.ly/3zMXFOp

Link to full program, including downloadable slidesets:
https://bit.ly/3iwN9Ub